General Internal Medicine

NCI-CCC Myeloma Tumor Board Question

Questions discussed in this category

How extensive of a workup do you do for systemic AL amyloidosis for a patient with a resected amyloidoma, localized AL amyloid deposition in their airway or lungs, who has no other symptoms?

Would you do a 24-hour urine and echocardiogram in all of these patients? Cardiac biomarkers, PT/PTT, or any other such blood tests?

3 Answers available

What is your approach for using anticoagulation/aspirin in patients with multiple myeloma?

2 Answers available

What infectious prophylaxis do you use for patients with newly diagnosed multiple myeloma?

How do you decide how long to continue?

1 Answer available

How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?

Is a repeatedly abnormal serum immunofixation all it takes for MGUS?

2 Answers available

Papers discussed in this category

Lancet Oncol, 2019 Oct 23

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

Br J Haematol, 2021 Aug 15

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.

Blood, 2022 Dec 08

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.

Haematologica, 2013-01

Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.

The Lancet. Haematology, 2015 May 06

Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.

European respiratory review : an official journal of the European Respiratory Society, 2017 Sep 06

The lung in amyloidosis.

Mayo Clinic proceedings, 2017-06

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience.

Blood Cancer J, 2022 Sep 14

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.

Related Topics in General Internal Medicine